Genetic re-direction of canine primary T cells for clinical trial use in pet dogs with spontaneous cancer.
Genetic re-direction of canine primary T cells for clinical trial use in pet dogs with spontaneous cancer.
复制标题
DOI：
10.1016/j.xpro.2021.100905
复制
发表时间：
2021-12-17
期刊：
影响因子：
--
通讯作者：
Mason NJ
中科院分区：
文献类型：
--
作者：
Rotolo A;Atherton MJ;Kasper BT;Haran KP;Mason NJ
具有免疫能力的宠物狗会发展出自发性的、类似人类的癌症，代表着研究嵌合抗原受体(CAR)疗法的平行患者群体。我们已经优化了一种基于逆转录病毒的方案，可以高效地转导健康和携带肿瘤的狗的初级T细胞。虽然转导效率和CAR-T扩增在不同的狗之间存在差异，但与以前的方案相比，CAR的表达通常更高和更稳定，从而使人类和比较肿瘤学研究人员能够将狗作为人类CAR-T细胞研究的临床前模型。有关本议定书的使用和执行的完整细节，请参阅。犬癌患者是CART评估的宝贵免疫活性资源RD114逆转录病毒和犬特异性珠使CAR高效稳定表达犬CART细胞可以有效扩增用于临床犬类试验CART临床试验犬CART临床试验是可行的，并可为人类CART方案设计提供信息，免疫能力强的宠物狗会发展成自发性的、类似人类的癌症，代表了平行患者群体的嵌合抗原受体(CAR)治疗的研究。我们已经优化了一种基于逆转录病毒的方案，可以高效地转导健康和携带肿瘤的狗的初级T细胞。虽然转导效率和CAR-T扩增在不同的狗之间存在差异，但与以前的方案相比，CAR的表达通常更高和更稳定，从而使人类和比较肿瘤学研究人员能够利用狗作为人类CAR-T细胞研究的临床前模型。
Immunocompetent pet dogs develop spontaneous, human-like cancers, representing a parallel patient population for the investigation of chimeric antigen receptor (CAR) therapies. We have optimized a retrovirus-based protocol to efficiently CAR transduce primary T cells from healthy and tumor-bearing dogs. While transduction efficiencies and CAR-T expansion vary among dogs, CAR expression is typically higher and more stable compared with previous protocols, thus enabling human and comparative oncology researchers to use the dog as a pre-clinical model for human CAR-T cell research. For complete details on the use and execution of this protocol, please refer to. Canine cancer patients are a valuable immunocompetent resource for CART evaluation RD114 retrovirus and dog-specific beads enable high and stable CAR expression Canine CART cells can be effectively expanded for clinical use in canine trials Canine CART clinical trials are feasible and can inform human CART protocol design Immunocompetent pet dogs develop spontaneous, human-like cancers, representing a parallel patient population for the investigation of chimeric antigen receptor (CAR) therapies. We have optimized a retrovirus-based protocol to efficiently CAR transduce primary T cells from healthy and tumor-bearing dogs. While transduction efficiencies and CAR-T expansion vary among dogs, CAR expression is typically higher and more stable compared with previous protocols, thus enabling human and comparative oncology researchers to utilize the dog as a pre-clinical model for human CAR-T cell research.
登录
查看更多内容
影响因子：
11.4
作者：
Milone MC;O'Doherty U
通讯作者：
O'Doherty U
影响因子：
50.3
作者：
Rotolo A;Caputo VS;Holubova M;Baxan N;Dubois O;Chaudhry MS;Xiao X;Goudevenou K;Pitcher DS;Petevi K;Kachramanoglou C;Iles S;Naresh K;Maher J;Karadimitris A
通讯作者：
Karadimitris A
DOI：
10.1007/978-1-61779-095-9_8
发表时间：
2011-01-01
期刊：
VIRAL VECTORS FOR GENE THERAPY: METHODS AND PROTOCOLS
影响因子：
--
作者：
Giry-Laterriere, Marc;Verhoeyen, Els;Salmon, Patrick
通讯作者：
Salmon, Patrick
影响因子：
82.9
作者：
Fraietta JA;Lacey SF;Orlando EJ;Pruteanu-Malinici I;Gohil M;Lundh S;Boesteanu AC;Wang Y;O'Connor RS;Hwang WT;Pequignot E;Ambrose DE;Zhang C;Wilcox N;Bedoya F;Dorfmeier C;Chen F;Tian L;Parakandi H;Gupta M;Young RM;Johnson FB;Kulikovskaya I;Liu L;Xu J;Kassim SH;Davis MM;Levine BL;Frey NV;Siegel DL;Huang AC;Wherry EJ;Bitter H;Brogdon JL;Porter DL;June CH;Melenhorst JJ
通讯作者：
Melenhorst JJ
影响因子：
7.2
作者：
Panjwani, M. Kazim;Atherton, Matthew J.;Mason, Nicola J.
通讯作者：
Mason, Nicola J.